Athenex, Inc. (NASDAQ:ATNX – Get Rating) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 3,030,000 shares, a decrease of 12.7% from the October 31st total of 3,470,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 2.7 days.
Athenex Price Performance
Shares of ATNX stock opened at $0.20 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.49 and a debt-to-equity ratio of 3.08. The business's fifty day simple moving average is $0.21 and its 200-day simple moving average is $0.41. Athenex has a 12-month low of $0.16 and a 12-month high of $1.74.
Get Athenex alerts:Athenex (NASDAQ:ATNX – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. Athenex had a negative net margin of 145.05% and a negative return on equity of 727.79%. The company had revenue of $33.53 million for the quarter, compared to analyst estimates of $28.80 million. During the same period in the prior year, the company earned ($0.33) earnings per share. As a group, analysts expect that Athenex will post -0.63 earnings per share for the current year.
Institutional Trading of Athenex
Hedge funds have recently bought and sold shares of the business. Millennium Management LLC increased its holdings in Athenex by 104.1% in the 2nd quarter. Millennium Management LLC now owns 4,578,195 shares of the company's stock valued at $1,874,000 after purchasing an additional 2,335,225 shares during the last quarter. Perceptive Advisors LLC raised its stake in Athenex by 14.8% during the 3rd quarter. Perceptive Advisors LLC now owns 15,532,467 shares of the company's stock worth $4,178,000 after acquiring an additional 2,000,000 shares in the last quarter. Victory Capital Management Inc. raised its stake in Athenex by 15,027.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,616,203 shares of the company's stock worth $435,000 after acquiring an additional 1,605,519 shares in the last quarter. Empery Asset Management LP acquired a new stake in Athenex during the 3rd quarter worth $391,000. Finally, UBS Group AG increased its stake in Athenex by 173.3% in the third quarter. UBS Group AG now owns 1,496,764 shares of the company's stock valued at $403,000 after purchasing an additional 949,096 shares during the period. Institutional investors and hedge funds own 29.41% of the company's stock.About Athenex
(Get Rating)
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies.
Read More
- Get a free copy of the StockNews.com research report on Athenex (ATNX)
- Is Salesforce Stock a Bargain Down Here?
- Intel is a Sleeping Giant Ready to Awaken
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.